Archive for the ‘Pharmaceutical marketing’ tag
Jin Si Ping for Parkinson’s
Interesting print ad campaign for a Parkinson’s Disease drug treatment from China.
Stopping tremor, Jin Si Ping beats Parkinson’s disease effectively.
Advertising Agency: Euro RSCG Life, Shanghai, China
Creative Director: Jane Huang
Art Director: Handsome Wong
Copywriters: Jane Huang, Dodo Liu
Photographer: Eric Zhang
Morethanmedication.ca Pfizer TV commercial
Advertiser: Pfizer
Agency: Zig Toronto
Creative Director: Martin Beauvais
Art Director: Niall Kelly
Copywriter: Goeff Morgan
Agency Producer: Dave Medlock
Executive Producer: James Davis
Producer: Kelly King
DoP: John Houtman
Director: John Mastromonaco
Production Company: Untitled Films, Toronto
Country: Canada
SpecTab TV commercial
Propaganda-like commercial for Spectab, an alcohol effect reducer.
Credits:
Brand: SpecTab
Title: Onovalov’s Statue
Client: Jelfa
Spectab - a pill reducing effects of alcohol (Anti-Hangover remedy).
URL: SpecTab.pl
Advertising Agency: Change Integrated, Warsaw, Poland
Agency website: http://www.goforchange.pl
Creative Directors: Ryszard Sroka, Jakub Korolczuk, Rafal Gorski
Art Director: Adam Szczepocki
Copywriter: Franek Toeplitz
Sculpturer: Wojciech Zasadni
Others: Joanna Zielinska, Piotr Sroka, Konrad Grzegorzewicz, Radoslaw Duda, Adam Smereczynski, Marcin Trybulski, Maciek Topolski
Released: June 2008
How to Create a Blockbuster
What do the pharmaceutical and entertainment industries have in common? More than you might think, says John Quelch. For starters, both run a greater risk in not pursuing the blockbuster than they do in pursuing it
The importance of blockbusters has been challenged recently by Chris Anderson’s long tail theory that you can make money in many creative industries by selling specialized products to niche markets identified via the internet. For example, the new CEO of GlaxoSmithKline, the pharmaceuticals giant, likens the search for blockbusters to “finding a needle in a haystack when you need it.” He also worries that a company is at risk if sales depend too much on one or two megabrands that could run into lawsuits from generic competitors or regulatory challenges.
